Evidence map›Paper›PMID 34510919›Full record

ArticleCephalalgia : an international journal of headache2022

The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic.

Esme Ekizoglu, Haşim Gezegen, Pınar Yalınay Dikmen, Elif Kocasoy Orhan, Mustafa Ertaş, Betül Baykan

Open access · hybridAbstract read
In one paragraph

Article in Cephalalgia : an international journal of headache, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Characteristics of Oral Adverse Effects following COVID-19 Vaccination and Similarities with Oral Symptoms in COVID-19 Patients: Taste and Saliva Secretory Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. A review of neurological side effects of COVID-19 vaccination.European journal of medical research · 2023
    Review
  19. Editorial: Emerging trends in headache.Frontiers in pain research (Lausanne, Switzerland) · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Esme EkizogluIstanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Haşim GezegenIstanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Pınar Yalınay DikmenAcıbadem Mehmet Ali Aydınlar University School of Medicine, Department of Neurology, Istanbul, Turkey.
Elif Kocasoy OrhanIstanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Mustafa ErtaşIstanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Betül BaykanIstanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey.
Istanbul University · TRKent Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHeadache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache.

methodsThe characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire.

resultsA total of 1819 healthcare personnel (mean age: 44.4 ± 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey; 209 (11.4%) had been infected with COVID-19. A total of 556 participants (30.6%) reported headache with significant female dominance (36.1% vs. 19.3%), 1.8 ± 3.5 (median: 1; IQR: 0-2) days following vaccination. One hundred and forty-four participants (25.9%) experienced headache lasting ≥3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 [95% CI 1.74-2.68] and 1.65 [1.24-2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 [95% CI 1.82-10.2] and OR = 4.84 [95% CI 2.84-8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 [95% CI 1.15-2.08]) with vaccine-related headache among the common comorbidities.

conclusionHeadache is observed in 30.6% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.

Indexed as

COVID-19COVID-19 VaccinesAdultDelivery of Health CareFemaleHeadacheHealth PersonnelHumansMiddle AgedPandemicsCOVID-19 Vaccinesadverse eventCOVID-19 vaccineheadachevaccinationvaccine

Identifiers

PMID34510919
PMCPMC8988457
OpenAlexW3201103731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.